Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record.

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Open access
Lagging, Martin, Romero, Ana I., Westin, Johan, Norkrans, Gunnar, Dhillon, Amar P., Pawlotsky, Jean-Michel, Zeuzem, Stefan, von Wagner, Michael, Negro, Francesco, Schalm, Solko W., Haagmans, Bart L., Ferrari, Carlo, Missale, Gabriele, Neumann, Avidan U., Verheij-Hart, Elke, Hellstrand, Kristoffer·2006·Hepatology

Abstract

Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP-10 levels prior to treatment with pegylated interferon-α-2a and ribavirin. Significantly lower IP-10 levels were observed in patients achieving a rapid viral response (RVR) ( P < .0001), even in those with body mass index (BMI) ≥ 25 kg/m2 ( P = .004) and with baseline viral load ≥ 2 million IU/mL ( P = .001). Similarly, significantly lower IP-10 levels were observed in patients obtaining a sustained viral response (SVR) ( P = .0002), including those having higher BMI ( P < .05), higher viral load ( P = .0005), and both higher BMI and viral load ( P < .03). In multivariate logistic regression analyses, a low IP-10 value was independently predictive of both RVR and SVR. A baseline cutoff IP-10 value of 600 pg/mL yielded a negative predictive value (NPV) of 79% (19/24) for all genotype 1–infected patients, which was comparable with that observed using a reduction in HCV-RNA by at least 2 logs after 12 weeks of therapy (NPV 86%; 19/22); by combining the two, 30 of 38 patients (NPV 79%) potentially could have been spared unnecessary therapy. In patients having both higher BMI and viral load, cut-off levels of 150 and 600 pg/mL yielded a positive predictive value (PPV) of 71% and NPV of 100%, respectively. In conclusion , pretreatment IP-10 levels predict RVR and SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load. A substantial proportion of the latter patients may achieve SVR in spite of unfavorable baseline characteristics if their pretreatment IP-10 level is low. Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.21407

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 216

Metadata

Authors
Lagging, M., Romero, A. I., Westin, J., Norkrans, G., Dhillon, A. P., Pawlotsky, J.-M., Zeuzem, S., von Wagner, M., Negro, F., Schalm, S. W., Haagmans, B. L., Ferrari, C., Missale, G., Neumann, A. U., Verheij-Hart, E., & Hellstrand, K.
Venue
Hepatology
Published
2006-12
Volume
44
Issue
6
Pages
1617-1625
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2001360631
Cited by
216
References
0
FWCI
7.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. https://app.cochat.ai/papers/10.1002/hep.21407
The paper
Lagging, M., Romero, A. I., Westin, J., Norkrans, G., Dhillon, A. P., Pawlotsky, J.-M., Zeuzem, S., von Wagner, M., Negro, F., Schalm, S. W., Haagmans, B. L., Ferrari, C., Missale, G., Neumann, A. U., Verheij-Hart, E., & Hellstrand, K. (2006). IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. https://doi.org/10.1002/hep.21407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.